Related Experiment Video
Updated: Aug 5, 2026

Production and Testing of Antimicrobial Peptides and Their Mimics
Published on: April 10, 2026
Antimicrobial peptides in anti-infective and immunomodulatory applications: Mechanisms, challenges, and emerging
Yan-Lin Wang1,2, Ya-Qian Yang1,2, Yu-Yang Zhou1,2
1Engineering Laboratory of Peptides of Chinese Academy of Sciences, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), State Key Laboratory of Genetic Evolution & Animal Models, Sino-African Joint Research Center, New Cornerstone Science Laboratory, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650201, China.
Abstract:
Antimicrobial Peptides (AMPs) evolutionarily conserved effectors of innate immunity, have emerged as multifunctional agents with broad-spectrum antimicrobial activity, immunomodulatory capabilities, and potential applicability in cancer therapy. Despite their functional diversity and biological potency, the clinical translation of AMPs remains constrained by significant challenges, including proteolytic instability, hemolytic toxicity, high production costs, and protracted development pipelines. This review examines how the diverse molecular mechanisms through which AMPs exert antimicrobial effects-including membrane disruption, intracellular targeting, and immunomodulation-are intrinsically linked to their structural diversity and ecological breadth. We critically evaluate engineering strategies that improve developability, including rational sequence modification, nano/targeted delivery, optimized formulations, and combination regimens with antibiotics or bacteriophages. As a complementary perspective, we briefly summarize recent progress in computational prediction and AI-driven screening/design for AMP discovery and multi-objective optimization, while highlighting major limitations such as dataset bias, scarcity of reliable negative data, and experimental validation bottlenecks. Beyond infectious disease, we discuss the impact of AMPs on reshaping the tumor microbiota-immune axis, revealing a dual function in both microbial control and immune regulation within oncogenic contexts. Overall, this review provides a balanced appraisal of evidence and translational pathways for advancing AMP-based therapeutics.
Related Concept Videos
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Humoral Immune Responses
